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Abstract
Background—The parametric g-formula can be used to estimate the effect of a policy, 
intervention, or treatment. Unlike standard regression approaches, the parametric g-formula can be 
used to adjust for time-varying confounders that are affected by prior exposures. To date, there are 
few published examples in which the method has been applied.
Methods—We provide a simple introduction to the parametric g-formula and illustrate its 
application in analysis of a small cohort study of bone marrow transplant patients in which the 
effect of treatment on mortality is subject to time-varying confounding.
Results—Standard regression adjustment yields a biased estimate of the effect of treatment on 
mortality relative to the estimate obtained by the g-formula.
Conclusions—The g-formula allows estimation of a relevant parameter for public health 
officials: the change in the hazard of mortality under a hypothetical intervention, such as reduction 
of exposure to a harmful agent or introduction of a beneficial new treatment. We present a simple 
approach to implement the parametric g-formula that is sufficiently general to allow easy 
adaptation to many settings of public health relevance.
Imagine an oncologist knocks on your door with the following problem: she wants to know 
how much she could reduce mortality among her bone marrow transplant patients by 
prescribing a new drug that prevents graft-versus-host disease, a side effect of allogeneic 
marrow transplantation.1 While graft-versus-host disease is associated in observational 
studies with an increased risk of mortality, it also reduces the risk of leukemia relapse – 
thus, any drug that prevents graft-versus-host disease may have the very undesirable side 
effect of increasing the rate of relapse.2 She wants to compare the mortality in her cohort 
with what mortality would be in that same cohort if they had taken this new drug. We cannot 
answer this question with a regression model because leukemia relapse is a risk factor for 
mortality and subsequent graft-versus-host disease and it will also decrease the incidence of 
Corresponding Author: Alexander Keil, Department of Epidemiology, CB 7435, University of North Carolina, Chapel Hill, NC 
27599-7435. akeil@unc.edu. T: 919-966-6652. F: 919-966-2089. 
HHS Public Access
Author manuscript
Epidemiology. Author manuscript; available in PMC 2015 January 29.
Published in final edited form as:













subsequent relapse (i.e. relapse is a confounder affected by exposure).3, 4 However, we can 
answer this question using the g-formula.
The g-formula is an analytic tool for estimating standardized outcome distributions using 
covariate (exposure and confounders) specific estimates of the outcome distribution.5The g-
formula can be used to estimate familiar measures of association, such as the hazard ratio. In 
the current paper, we address the oncologist’s question: we compare observed mortality in 
our cohort with the expected mortality in that cohort under the new treatment.
Epidemiologists often use regression models (for example, the Cox proportional hazards 
model) to adjust for confounding; this is equivalent to estimating stratum-specific hazard 
ratios and then averaging the information-weighted hazard ratios. When some of those 
confounders are also causal intermediates, this amounts to adjusting away some of the effect 
of exposure.6, 7 The g-formula works differently: first, one finds weighted averages of the 
stratum-specific hazards, and then those averaged (standardized) hazards are combined in a 
summary hazard ratio. Thus, bias resulting from time-varying covariates that can be both 
confounders and causal intermediates is a shortcoming of using regression models to control 
for confounding, rather than a general principle of observational data analysis.8, 9 The g-
formula is a tool that overcomes this shortcoming, but its use in the literature has been 
sparse – we could find only 9 examples using observational data.8, 10-17 We hypothesize that 
the dearth of software packages and lack of useful, yet simple, examples of the g-formula 
have been the main barriers to broader use.
We show how the g-formula can be used with standard software tools that many 
epidemiologists already employ, and we illustrate it using publicly-available data from a 
small cohort study with accompanying SAS code in an eAppendix. We illustrate how we 
can estimate the net (total) effect of a hypothetical treatment to prevent graft-versus-host 
disease on mortality and compare the g-formula approach with a regression approach. The 
g-formula (as with any statistical method) relies on making assumptions in order to make 
sense of the complex processes underlying the data. We discuss possible ways to assess how 




Using regression methods to control confounding requires making the assumption that the 
effect measure is constant across levels of confounders included in the model. Alternatively, 
standardization allows us to obtain an unconfounded summary effect measure without 
requiring this assumption. The g-formula is a generalization of standardization and can be 
expressed similarly. For example, the 10-year risk of death for a group of individuals, 
standardized across some dichotomous (1,0) risk factor Z could be expressed as
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where Σz indicates that we are summing over each possible value of Z, and Pr (Z = z) is the 
probability that Z takes on the value z in the reference population. If the 10-year risk of 
death among the group with Z=1 was 0.1 and the risk among the group with Z=0 was 0.05, 
and we were studying a population with a 60 individuals with Z=1 and 40 individuals with 
Z=0, the Z-standardized 10-year risk of death would be 0.1*(60/100)+0.05*(40/100) = 0.08.
The g-formula relies on this same set of calculations. Suppose now that we have a cohort of 
50-year-old men and we wish to estimate the change in 10-year risk of death from some 
exposure, X, that has no effect on mortality among 50-55 year olds but increases mortality 
after age 55. The overall 10-year risk of death, Pr(death10=1), could be calculated using the 
probabilities expressed by the g-formula:
Assume 50% are exposed at the start. As shown in the calculations from Table 1, if the 
probability of death in our cohort after 5 years (at age 55 - death5) is 0.025 for everyone and 
the conditional probability of death between 5 and 10 years of follow-up (i.e. between age 
55 and 60) is 0.06 for exposed and 0.051 for unexposed individuals, the overall standardized 
10-year risk of death (Pr(death10=1)) would be 0.08. We consider the probability of death in 
the second period to be conditional because we condition (restrict) our data to the 
individuals still alive at the beginning of year 6. The overall standardized risk is often 
referred to as the “natural course”, because we are estimating the risk under no 
interventions. In this setting (in which we can observe all covariate specific probabilities), 
the observed 10-year risk will equal the 10-year risk calculated using the “natural course.”
Use of the g-formula for effect estimation proceeds using the standardization formula above 
and substituting new values for probabilities of exposure defined by a hypothetical 
intervention. For example, if we wished to estimate the effect of exposure on the 10-year 
risk of death, we would use the g-formula to calculate the risk of death if we intervened to 
make all individuals “always exposed “ (i.e. set Pr(X = 1∣age) = 1.0 (and Pr(X =0∣age) = 0.0) 
regardless of age) versus the risk if we intervened to make all individuals “never exposed” 
(e.g. set Pr(X =0∣age) = 1.0) (and Pr(X = 1∣age) = 0.0)). As shown in Table 1, we substitute 
1.0s (and 0.0s) into the standardization formula for these conditional exposure probabilities 
and arrive at a 10-year risk for the intervention “always exposed” of 0.084 and for the 
intervention “always unexposed” of 0.075 (g-formula standardized risk difference = 0.009). 
For an intervention in which we expose all participants in the last 5 years only (the treatment 
plan “expose if still alive at 5 years”), we would “intervene” by setting conditional 
probabilities Pr(X∣ age > 50) to 1.0 and Pr(X∣ age ≤ 55 to the conditional proportions 
observed in the original data (risk=0.084).
The parametric g-formula
While standardization using the g-formula is simple enough to do by hand in our 
hypothetical example, epidemiologic studies often have richer covariate sets and longer 
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periods of follow-up. In such studies, stratification by many covariates can quickly lead to 
strata in which there are not enough data to calculate the conditional probabilities, and use of 
continuous covariates does not allow this stratification approach. Instead of directly 
calculating every conditional probability, we can use parametric regression modeling to 
calculate the conditional probabilities used to carry out computations shown above. Further, 
we can simulate data from the conditional probability distributions to approximate 
standardization. Robins referred to this approach of using modeled conditional probabilities 
to estimate standardized effect measures as the parametric g-formula.14, 18 The data from 
our illustrative example and SAS code to carry out our algorithm are provided in 
eAppendices 1 through 4.
Illustrative example
We use the parametric g-formula to estimate the hazard ratio comparing mortality in a 
cohort of bone marrow transplant recipients (described in detail by Copelan etal19 and by 
Klein and Moeschberger) 20 under different treatments by a hypothetical drug that prevents 
graft-versus-host disease. Use of the g-formula for our example was motivated by 
hypothesized time-varying confounding shown in the causal diagram in Figure 1, and by the 
desire to estimate the reduction in mortality from an intervention that could prevent graft-
versus-host disease.
Study population—The study population arose from a multicenter trial of leukemia 
patients and comprises 137 individuals prepared for bone marrow transplants under a 
radiation-free regimen at four medical centers. Allogeneic bone marrow transplants were 
performed between 1 March 1984 and 30 June 1989, and patients were followed until death 
or administrative censoring at 5 years following transplant. Baseline covariates at time of 
transplant included age, sex, leukemia type (acute lymphocytic or acute myeloid leukemia), 
wait time from leukemia diagnosis to transplantation, and cytomegalovirus immune status 
(yes or no). Patients were followed to assess when, if at all, platelets returned to the normal 
range (as a measure of immune function) and the patient experienced leukemia relapse.
We illustrate how to apply the parametric g-formula to the cohort of bone marrow transplant 
recipients to estimate the effect of a hypothetical intervention that prevents graft-versus-host 
disease from occurring. While the cohort is small, our example can be easily adapted to 
larger observational studies with long-term follow-up.
The parametric g-formula algorithm for the bone marrow transplant data—We 
use a 3-step algorithm for the parametric g-formula to estimate hazard ratios comparing: a 
new drug that prevents graft-versus-host disease from occurring during follow up 
(“prevented”) versus no intervention (“natural course”). We compare “natural course” to 
“prevented” as a measure of how effective a drug that prevents graft-versus-host disease 
would have been at preventing mortality in our cohort (or similar populations). We present 
the algorithm in compact form in Figure 2, and interested readers may find it of use to 
follow our algorithm with the SAS code and data given in eAppendices 1-4 and the more 
formal (and technical) presentation of the g-formula of our data in eAppendix 5.
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Step 1) Probability modeling: We start with a person-period data set in which each record 
corresponds to one person-day and time-varying covariates are represented as (0,1) 
dichotomous variables for each person day. Within this person-period data, we fit a pooled 
logistic model (i.e. a logistic model fit to all person periods) to estimate the log-odds of each 
of the time-varying covariates (graft-versus-host disease, platelet level, relapse, death), for 
each person period (i.e. the conditional log-odds of the covariate taking on the value “1”).21 
We included time (i.e. days since transplant) in the model using a set of polynomial terms. 
Because we modeled the onset of graft-versus-host disease (and other time-varying 
covariates), the models for each covariate on day k were fit using only person-days for 
which the patient had not yet experienced each time-varying covariate on day k − 1. We 
transformed the log-odds of each covariate into probabilities using the transformation Pr(·) = 
exp (·)/(1+exp (·)).
Step 2) Monte Carlo sampling: From our original data of N=137 patients, we re-sampled 
with replacement M=137,000 “pseudo-patients,” retaining only baseline covariates. The 
sample should be as large as practical to minimize simulation error. This simulation is 
carried out as follows.
We simulated time-varying covariate and outcome data for each of the pseudo-patients using 
conditional probabilities generated in Step 1 and baseline covariates (with time-varying 
covariates set to 0 at baseline). Each pseudo-patient received values for these covariates on 
each day based on a draw from a Bernoulli distribution with the conditional mean given by 
the probability modeled in Step 1, above. Essentially, on each day k, we flipped biased coins 
to choose whether or not the pseudo-patient became exposed, experienced relapse, returned 
to normal platelet levels, was censored, or died, and the probability of a coin coming up 
“heads” depended on values of those covariates on prior days and the baseline covariates.
The dataset from this step is known as the “natural course” because there is no intervention. 
To ensure that covariate distributions from the “natural course” closely follow distributions 
in the observed data, we examined the Kaplan-Meier survival curve for death (Figure 4) as 
well as the complement of the Kaplan-Meier curves for time to onset of graft-versus-host 
disease, relapse, and normal platelet count (Figure 3). We fit multiple parametric forms for 
each model in Step 2 and based our final choice of model on how closely these graphs and 
covariate means from the “natural course” matched those in the observed data. For example, 
we compared the fit of models using linear, quadratic, cubic polynomial, quadratic spline, 
unrestricted cubic spline, and restricted cubic splines. Model components and coefficient 
values are given in eAppendix 6.
We repeated Step 2 using an intervention “prevented,” set graft-versus-host disease to 0 and 
generate all other covariates, forcing graft-versus-host disease to remain 0. By setting the 
values of graft-versus-host disease in the dataset, the proportion of deaths in the simulated 
dataset in which we set graft-versus-host disease=0 approximates the solution to the explicit 
formulas shown in our hypothetical example (in which the conditional probabilities of graft-
versus-host disease onset are all set to 0).
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Step 3) Effect estimation: We concatenated the datasets from Step 2, estimating the hazard 
ratio by comparing the hazards in the “natural course” dataset with those in the “prevented” 
dataset. This was done by using an indicator variable for the dataset (1=“natural course,” 
0=“prevented”) and using that indicator as the exposure variable in a Cox model.
To estimate confidence intervals for the hazard ratio, we repeated Steps 1-3 on 4000 samples 
of size 137 taken at random with replacement from the original data. The standard deviation 
(SD) of the 4000 log-hazard ratios approximates the standard error of the log-hazard ratio, 
and was used to calculate 95% confidence intervals (CIs) using the normal approximation: 
log-hazard ratio ±1.96*SD(log-hazard ratio).
Statistical methods for comparison
To compare the g-formula with standard methods, we estimated crude and covariate 
conditional hazard ratios (and 95% confidence intervals) for the effect of graft-versus-host 
disease on mortality using a Cox proportional hazards model for time-varying data (with 
observed data).22 We controlled for possible confounding by baseline and time-varying 
covariates by including indicator terms in the Cox model. A test of proportional hazards in 
crude and regression-adjusted models indicated that a summary hazard ratio over the five-
year course of the study was adequate.
RESULTS
Patients had a median age of 28 years (interquartile range=21-35), and 60% were male 
(Table 2). Half of the patients tested positive for cytomegalovirus at baseline (n=68; 50%). 
In the first 5 years of the study, 72 patients developed graft-versus-host disease and 43 
patients relapsed. Platelet levels returned to normal for 88% of patients (n=120). Five years 
after receiving a transplant, 58% of the patients had died (n=80).
Regression adjustment
The crude hazard ratio comparing the hazard of all-cause mortality among patients with and 
without graft-versus-host disease was 1.2 (95% CI=0.77-2.0; Table 3). The hazard ratio was 
unchanged after regression adjustment for baseline covariates, but was notably larger after 
regression adjustment for baseline and time-varying covariates (hazard ratio=2.3 [95% 
CI=1.4-3.9]).
G-formula
In the simulated data under the natural course, the cumulative distribution functions for 
platelet count, relapse, death, and graft-versus-host disease closely followed those in the 
observed data (Figures 3 and 4). The 5-year cumulative risk of death using the g-formula 
under the natural course was 61%. The hazard ratio comparing the “natural course” to 
“prevented” (referent) was 1.1 (95% CI=0.91, 1.3).
DISCUSSION
In our analysis of survival data using a simple and yet easily adaptable application of the g-
formula, we estimated the effects on mortality of an intervention to prevent graft-versus-host 
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disease immediately after bone marrow transplant. Almost 60% of the bone marrow 
transplant patients in this cohort experienced graft-versus-host disease under the natural 
course; however, compared with a hypothetical intervention to prevent graft-versus-host 
disease, under the natural course we observed an increase in the relative mortality hazard of 
only 10%. Preventing graft-versus-host disease does not appear to markedly reduce 
mortality risk because other factors that influence the risk of subsequent mortality, such as 
leukemia relapse, are not decreased by the hypothetical intervention to prevent graft-versus-
host disease. Rather, preventing graft-versus-host disease may increase the rate of relapse: 
42% of “pseudo-individuals” experienced relapse under the “prevented” intervention, 
whereas 33% experienced relapse under the “natural course.” These observations agree with 
the typically coincident occurrences of graft-versus-host disease and graft-versus-leukemia, 
in which donor cells attack residual leukemia cells in the transplant recipient and may help 
to prevent relapse. Graft-versus-host disease has been observed to correlate with a lower rate 
of leukemia relapse and is hypothesized to reduce the probability of relapse through immune 
mediation processes, of which normal platelet count is an indicator.1
Cox regression analysis with adjustment for time-varying covariates suggested a 
substantially higher mortality hazard for persons who have graft-versus-host disease when 
compared with those who do not have this disease. Because the Cox model cannot 
appropriately control time-varying confounding when the confounders are causal 
intermediates, we hypothesize that the Cox model overestimates the total effect of graft-
versus host disease on mortality. Therefore, the difference between the g-formula estimate 
and the regression adjustment method may be due, in part, to over-adjustment, which 
introduces bias into our estimate of the total effect of graft-versus-host disease.23 In 
addition, another reason for the difference between the g-formula estimate and the adjusted 
Cox regression model estimate is that these analyses estimate different quantities. The g-
formula yielded an estimate of the hazard ratio comparing the observed mortality in our 
cohort (the natural course) with the expected mortality in that cohort under the new 
treatment. The Cox model yielded an estimate of the mortality hazard for those with graft-
versus-host disease compared with those without graft-versus-host disease.24
The g-formula can be used to estimate risk ratios or differences, which are easier to interpret 
and less subject to some biases than are hazard ratios.25 Like Westreich et al, 14 we have 
estimated hazard ratios as effect measures to ease the comparison with results from 
conventional methods. However, when a confounder is a strong predictor of the outcome, 
marginal hazard ratios from the g-formula and conditional hazard ratios from regression 
approaches may differ even if there is no time-varying confounding, a condition known as 
“non-collapsibility.”26 Because the set of time-varying covariates includes relapse, a strong 
predictor of mortality, this is not a trivial concern for our example, but adjustment via 
regression modeling simply replaces confounding bias with bias due to conditioning on an 
effect of the exposure. However, the g-formula estimates a hazard ratio we could observe in 
a population intervention (marginal, or standardized to the population), and is arguably more 
useful than a conditional hazard ratio when estimating the public health impact of 
interventions.
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There is little knowledge about how potential time-varying confounding by relapse and 
platelet levels affects estimates of excess mortality due to graft-versus-host disease. G-
methods (the body of methods that derive from the g-formula, including structural nested 
models and marginal structural models) may provide an avenue toward a clearer 
understanding. G-methods have previously been shown to yield results congruent with 
clinical trial data (where time-varying confounding may be minimized) in situations where 
conventional analyses of observational data yield incongruous estimates.14, 27, 28 There are 
few examples in the literature in which the parametric g-formula has been used to estimate 
the effects of policies or interventions. Robins8, 10 estimated the effect of interventions 
capping arsenic exposure on the risk of lung cancer in a cohort 8,047 copper smelter 
workers in Montana. Ahern et al. 11 used the parametric g-formula to estimate the effect of 
interventions to change neighborhood smoking norms on the prevalence of smoking using 
data collected from 4000 New York City residents. Using data from the Nurses’ Health 
Study, Taubman et al. 12 estimated the 20-year risk (cumulative incidence) of coronary heart 
disease under interventions on dietary factors, exercise, smoking, alcohol consumption, and 
body mass index; using data from the same study, Danaie et al. 16 estimated the effects of 
similar interventions on the 24-year risk of type-2 diabetes and Garcia-Aymerich et al. 17 
estimated the effect of joint interventions on physical activity and weight loss on adult onset 
asthma incidence. In a cohort of 8392 HIV-infected participants in the HIV-CAUSAL 
collaboration, Young et al. 13 applied the parametric g-formula to estimate 5-year mortality 
risks under seven dynamic treatment regimes to determine the optimal CD4 count at which 
to begin antiretroviral therapy. Westreich et al. 14 used the parametric g-formula to estimate 
hazard ratios comparing the hazard of AIDS or death among 1498 HIV-infected patients 
enrolled in the Multicenter AIDS Cohort Study and the Women’s Interagency HIV Study 
had all study participants received antiretroviral therapy with the hazard had none of the 
study participants received therapy. Finally, using data from a cohort of 3,002 textile 
workers, Cole et al. 15 estimated effect on lung cancer mortality if recent occupational limits 
on annual exposures to chrysotile asbestos fibers had been in place during the workers’ 
tenure.
In all of these studes except the one by Ahern et al., the potential for time-varying 
confounding precluded the use of conventional regression approaches. In all cases, the g-
formula naturally lent itself to estimating the effects of potential interventions. Rather than 
estimating the more familiar contrast in measures of disease occurrence for a unit change in 
the exposure, the g-formula provides an estimate of outcome occurrence under a specific 
treatment regime under study. While regression adjustment and the g-formula allow for 
estimation of “etiologic” hazard ratios, only the g-formula easily allows estimation of the 
effect of preventing graft-versus-host disease in the population, which may be more useful 
for informing population-level interventions.
We must make several assumptions when using of the g-formula to estimate the effects of 
exposure on an outcome in observational data.8 We provide a brief discussion of these 
assumptions for our analysis, which are reviewed in depth elsewhere.29, 30 These 
assumptions are not unique to the g-formula, but estimating effect measures in the g-formula 
requires explicitly confronting these assumptions, which may be valuable in informing the 
interpretation of observational studies.
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As epidemiologists, we may strive to measure and control for strong confounders of the 
exposure-outcome relationship to avoid making inference based on spurious relationships, 
and we often assume we have been successful – this is the assumption of conditional 
exchangeability. In our g-formula example, we impute the potential outcomes for each 
person based on an evolving covariate history generated by predictive models for the 
exposure, covariates and the outcome. If there were a strong, unmeasured, baseline 
confounder, we would have omitted an important variable from both the exposure model 
and the outcome model. However, as Robins et al18 note, the exposure model does not need 
to be correct in order to make inference from the g-formula. To see this, recall our original 
hypothetical example in which, to make interventions, the probability of exposure is set to 0 
in the “prevent” intervention. Thus, because we “set” exposure, the hazard under some 
intervention will be subject to bias only through the model for the outcome. The practical 
consequence of this is that unmeasured confounder bias should be (approximately) the same 
under the g-formula and a standard regression model, when we are comparing two 
interventions. However, unmeasured confounding bias may be greater in the g-formula 
when comparing an intervention versus the “natural course,” since this analysis requires a 
model for the exposure.
In more complex settings, such as if the omitted confounder were also a cause of another 
time-varying covariate, the g-formula may be subject to more bias than conventional models 
due to unmeasured confounding. Intuitively, this is because we could be accumulating bias 
over multiple models, rather than a single outcome model (as in the standard Cox model). 
However, we should note that, in complex time-varying settings, conventional models 
require stratification over time-varying confounders, which may be problematic for reasons 
discussed above, and conventional models may not be able to estimate useful effect 
measures, such as the impact of an intervention on a population. The g-formula is not 
subject to either of these shortcomings. Ultimately, the impact of unmeasured confounding 
in the g-formula (versus conventional models) is an open question; future work will provide 
guidance to epidemiologists working in settings where unmeasured confounding is expected 
to be problematic.
While sensitivity analyses exist for examining robustness to the assumption of no 
unmeasured confounding,31 they are most informative when one can hypothesize both a 
source of confounding and the plausible levels of the strength of the confounder associations 
in the study.32 We know of no factors that could strongly influence the estimated effect of 
graft-versus-host disease on mortality, and so in the case of our g-formula example, the 
sensitivity of the hazard ratio to unmeasured confounding would either be purely speculative 
or be focused on finding the level of confounding that could explain the observed 
association.
Treatment version irrelevance
We assume the effect of exposure is the same whether we set it, as in the case of Step 5 of 
our algorithm or a clinical trial, or if it occurs naturally.33, 34 When we “intervene” to set 
graft-versus-host disease to 0 for all pseudo-patients in our Monte Carlo sample, treatment 
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version irrelevance means we assume that this emulates a process in which a researcher 
could prevent graft-versus-host disease. We hypothesize this assumption may be violated in 
our example, because acute and chronic forms of graft-versus-host disease may not affect 
mortality with the same magnitude.2 In this case, we could improve on how well we meet 
this assumption by including models for both chronic and acute graft-versus-host disease, as 
well as estimating effects for both on mortality. However, because we are estimating the 
population-averaged effect of graft-versus-host disease on mortality, such an analysis would 
not likely give substantially different results. Our analysis applies to graft-versus-host 
disease, as it occurs in populations similar to our cohort in which graft-versus-host disease 
can be either acute or chronic. Consistency requires that we specify interventions which are 
unambiguous.35 Thus, the sensitivity of the g-formula results to violations of treatment 
version irrelevance depends, in some respect, on how well one can emulate one’s analysis 
with a clinical trial.
As an anonymous referee pointed out, our analysis can be used to guide future clinical trials 
by informing on the effects of a drug that completely prevents graft-versus-host disease – 
our estimate of a 10% reduction in 5-year mortality could used to plan such a study. If one 
were to study the effect of, say, a population intervention that dictated an instantaneous shift 
in body-mass-index (BMI) category, then g-formula results would not estimate the effect we 
could observe in any clinical trial.35
Correct model specification
The parametric g-formula is especially vulnerable to the assumption of correct model 
specification, due to the use of multiple models. As an example from our study, if the true 
effect of wait time to transplant had a quadratic association with exposure and a cubic 
association with mortality, then we would have misspecified two models and would likely 
have introduced bias into the hazard ratio. Our g-formula algorithm allows informal 
checking of this assumption by comparing the observed data to the data simulated under the 
natural course (e.g. Figures 3 and 4). Nonetheless, similarity to the natural course cannot 
completely rule out model misspecification.18 The g-formula may not be ideal for 
hypothesisgenerating studies, in which causal relationships are more uncertain and model 
misspecification is potentially severe.
Summary, recommendations and conclusions
The g-formula does not require more information than standard methods to estimate effects 
of exposures or interventions, and its is not subject to bias due to stratifying on variables 
affected by exposure. The g-formula does not assume that the hazard ratio is homogenous 
over the levels of the confounders – that is, we are not restricted to estimating a summary 
hazard ratio that conditions on the covariates. Unlike methods that use stratification of the 
data by covariates, and then obtain a summary hazard ratio under the assumption of a 
constant hazard ratio over levels of the confounder, the g-formula permits us to obtain a 
summary hazard ratio without stratifying the effect measure over covariates. This relaxed 
assumption comes at the cost of wider confidence intervals, so there is a bias-variance trade-
off to consider when deciding if the g-formula is an appropriate statistical tool for an 
epidemiologic analysis. If one knows that time-varying confounding is not present, or that 
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exposure could not affect subsequent confounders, then standard regression methods may be 
more appropriate, due mainly to concerns about model misspecification in the g-formula. 
However, if time-varying confounding is possible, use of the g-formula provides some 
assurance that one is not introducing bias by inappropriately stratifying on effects of 
exposure, and it is useful to check results from standard regression models against those 
from the g-formula, as we have shown.
We could have estimated the hazard ratio for the marginal effect of graft-versus-host disease 
on mortality using inverse-probability weighted marginal structural models or adaptations of 
structural nested models.36-38 In principle, these models would yield similar effect estimates 
as our method, although our small data set would likely result in practical violations of 
additional assumptions necessary for inverse-probability-weighting methods,39 and, without 
knowledge about the baseline hazard of potential outcomes, structural nested models may 
yield larger confidence intervals.40 These methods may be more desirable when model 
misspecification is a primary concern, because they require fewer models than the g-
formula.18
Though the g-formula was first described in 1986 by Robins,8 the availability of rich data 
from large cohort studies and the acceleration of computing speeds have only recently made 
the method feasible for widespread use. While the g-formula may be more sensitive to 
model misspecification than standard regression models, we show how inappropriate control 
of time-varying confounding could lead to incorrect conclusions about the strength of the 
effect of graft-versus-host disease on mortality. Moreover, we illustrate how the g-formula 
allows estimation of the effects of realistic interventions and give concrete examples of 
situations in which the g-formula should be used by epidemiologists. We have provided both 
publicly available data and the SAS code as appendices to this paper. The current analysis 
represents the first published use of the g-formula for a time-varying exposure that can be 
easily replicated by other investigators using a real-world example. Future implementations 
of the g-formula can extend our example easily to an array of epidemiologic problems and 
further explore the impacts on inference from unmeasured confounding and model 
misspecification.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Directed acyclic graph showing hypothesized causal relationships among study variables for 
days k − 1 and k. This graph demonstrates bias in regression stratification methods in 
estimating the effect of exposure over time (GνHDk−1, GνHDk) on subsequent death when 
time-varying factors on confounding pathways (Relapsek) may be affected by prior 
exposure.
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Parametric g-formula algorithm for bone marrow transplant data.
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Incidence curves for (A.) death. (B.) return to normal platelet levels, (C.) relapse and (D.) 
graft-versus-host-disease (GvHD) from both observed (gray line) and g-formula natural 
course Monte Carlo (black line) data.
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Survival functions: observed from the bone marrow transplant data; from the natural-course 
intervention in the g-formula; and from the hypothetical intervention “prevented” graft-
versus-host disease (top line) after bone marrow transplants using the g-formula. The gray 
line indicates the observed survival curve, while the solid black lines indicate the survival 
curves from the Monte Carlo data for the g-formula interventions.
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Table 1
Estimating risk under interventions using the g-formula with the hypothetical example given in methods 
section of the main text.
G-formula component Value
Conditional probabilities
First 5 years PR(exposed): 0.5
Risk among exposed: 0.025
Risk among unexposed: 0.025
Last 5 years Pr(exposed): 0.5
Risk among exposed: 0.060
Risk among unexposed: 0.051
Risk under interventions
Observed/Natural course 0.051*(1/2)*(1-0.025*(1/2)) + 0.025*(1/2) +
0.060*(1/2)*(1-0.025*(1/2)) + 0.025*(1/2) = 0.080
Always exposed 0.051*(0)*(1-0.025*(0)) + 0.025*(0) +
0.060*(1)*(1-0.025*(1)) + 0.025*(1) = 0.084
Never exposed 0.051*(1)*(1-0.025*(1)) + 0.025*(1) +
0.060*(0)*(1-0.025*(0)) + 0.025*(0) = 0.075
Expose if survive to year 5 0.051*(0)*(1-0.025*(0)) + 0.025*(1/2) +
0.060*(1)*(1-0.025*(1)) + 0.025*(1/2) = 0.084
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Table 2
Characteristicsa of 137 patients receiving bone marrow transplants during treatment for leukemia at 4 study 
sites between 1985 and 1989.
Sex Male 80 (58)
Female 57 (42)
GvHD onset within 5 years No 65 (47)
Yes 72 (53)
Relapse within 5 years No 94 (69)
Yes 43 (31)
Return to normal platelet count within 5 years No 17 (12)
Yes 120 (88)
Leukemia type ALL 38 (28)
Low-risk AML 54 (39)
High-risk AML 45 (33)
CMV status at baseline Negative 69 (50)
Positive 68 (50)
Vital status 5 years after transplant Alive or censored 57 (42)
Dead 80 (58)
Age (years); median (IQR) 28 (21-35)
Days to transplant; median (IQR) 6 (4-8)
Follow up; median (IQR) 547 (183-1377)
Days to relapse; median (IQR) 467 (122-1363)
Days to normal platelets; median (IQR) 18 (14-27)
a
No. (%), unless otherwise specified
ALL indicates acute lymphocyte leukemia; AML, acute myeloid leukemia; IQR, interquartile range













Keil et al. Page 23
Table 3
Hazard ratios comparing the hazard of all-cause mortality between patients with and without graft-versus-host 
disease (regression) or comparing cohorts with and without hypothetical intervention to prevent graft-versus-
host disease (g-formula)
Method HR (95% CI)
Regression
Crude 1.2 (0.77-2.0)
Baseline adjusted a 1.2 (0.71-1.9)
Fully adjusted b 2.3 (1.4-3.9)
G-formula
Natural course vs. Prevent c 1.1 (0.91-1.3)
a
Baseline covariates include age at date of bone marrow transplant, wait time until transplant, sex, and cytomegalovirus status at baseline.
b
Adjusted for baseline covariates above and time-varying covariates, including days during which platelets had not returned to normal, cumulative 
days the patient had not experienced relapse, and indicators for relapse and platelets returning to normal on a given day.
c
Comparing the hazard of all-cause mortality between the entire cohort simulated under no intervention and the entire cohort of simulated to be 
unexposed (referent) at all time points.
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